Bal Pharma Past Earnings Performance
Past criteria checks 5/6
Bal Pharma has been growing earnings at an average annual rate of 41.1%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 11.9% per year. Bal Pharma's return on equity is 10.8%, and it has net margins of 2.2%.
Key information
41.1%
Earnings growth rate
40.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.9% |
| Return on equity | 10.8% |
| Net Margin | 2.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,392 | 74 | 604 | 0 |
| 31 Dec 23 | 3,270 | 35 | 601 | 0 |
| 30 Sep 23 | 3,220 | 32 | 589 | 0 |
| 30 Jun 23 | 3,048 | 24 | 571 | 0 |
| 31 Mar 23 | 3,042 | 26 | 561 | 0 |
| 31 Dec 22 | 2,958 | 29 | 542 | 0 |
| 30 Jun 22 | 2,802 | 43 | 494 | 0 |
| 31 Mar 22 | 2,812 | 56 | 478 | 0 |
| 31 Dec 21 | 2,780 | 72 | 459 | 0 |
| 30 Jun 21 | 2,692 | 59 | 426 | 0 |
| 31 Mar 21 | 2,505 | 47 | 426 | 0 |
| 31 Dec 20 | 2,135 | -34 | 425 | 0 |
| 30 Sep 20 | 1,936 | -73 | 438 | 0 |
| 30 Jun 20 | 1,741 | -95 | 469 | 0 |
| 31 Mar 20 | 1,711 | -122 | 508 | 0 |
| 31 Dec 19 | 1,924 | -52 | 529 | 0 |
| 30 Sep 19 | 2,081 | -15 | 537 | 0 |
| 30 Jun 19 | 2,206 | -21 | 519 | 0 |
| 31 Mar 19 | 2,250 | 38 | 519 | 0 |
| 31 Dec 18 | 2,264 | 29 | 579 | 0 |
| 31 Mar 18 | 2,093 | 28 | 543 | 0 |
| 31 Dec 17 | 2,111 | 14 | 487 | 0 |
| 31 Mar 17 | 2,289 | 18 | 471 | 0 |
| 31 Dec 16 | 2,210 | -3 | 455 | 0 |
| 30 Sep 16 | 2,120 | 13 | 431 | 0 |
| 30 Jun 16 | 2,016 | 16 | 396 | 0 |
| 31 Mar 16 | 1,983 | 14 | 387 | 0 |
| 31 Dec 15 | 1,959 | 47 | 580 | 12 |
| 30 Sep 15 | 1,925 | 33 | 567 | 12 |
| 30 Jun 15 | 1,861 | 29 | 327 | 0 |
| 31 Mar 15 | 1,875 | 36 | 336 | 0 |
| 31 Dec 14 | 1,846 | 48 | 542 | 9 |
| 30 Sep 14 | 1,857 | 54 | 535 | 9 |
| 30 Jun 14 | 1,836 | 51 | 292 | 0 |
| 31 Mar 14 | 1,789 | 51 | 512 | 9 |
| 31 Dec 13 | 1,720 | 58 | 444 | 8 |
| 30 Sep 13 | 1,631 | 55 | 433 | 8 |
| 30 Jun 13 | 1,552 | 50 | 243 | 0 |
Quality Earnings: 524824 has high quality earnings.
Growing Profit Margin: 524824's current net profit margins (2.2%) are higher than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524824's earnings have grown significantly by 41.1% per year over the past 5 years.
Accelerating Growth: 524824's earnings growth over the past year (187.4%) exceeds its 5-year average (41.1% per year).
Earnings vs Industry: 524824 earnings growth over the past year (187.4%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: 524824's Return on Equity (10.8%) is considered low.